Shenzhen Rentai Pharmatech Ltd

Shenzhen Jingtai Technology Co., Ltd.

Dongxu Yi

Jiajun Huang

Guobin Ren

Weijie Ji

Yang Liu

Jian Ma

Shuhao Wen

Peiyu Zhang

Guangxu Sun

Mingjun Yang

Xuekun Shi

Yanqi Zhang

Shigang Ruan

A crystalline form A of 2,2-bis(4-fluorophenyl)-2-phenylacetamide is provided. The crystalline form has good light stability, high temperature stability, and high humidity stability.

Crystalline form a of 2, 2-bis(4-fluorophenyl)-2-phenylacetamide and preparation method therefor and application thereof

Disclosed are eutectic form A of Elagolix and pyrimethamine, a preparation method therefor and a use thereof. Using Cu-Kα radiation, eutectic form A has characteristic peaks represented by a 2θ degree at 8.1±0.2°, 12.2±0.2°, 13.3±0.2° and 21.1±0.2° in an X-ray powder diffraction. Eutectic form A has a high purity, a good light radiation stability, a high temperature stability, a high humidity stability and an accelerated stability, is easy to store, and has a slow moisture absorption under the condition of relatively low humidity, wherein the weight gain of eutectic form A by moisture absorption is not more than 1.08% when the relative humidity increases from 0 to 60% RH. Production conditions for eutectic form A are easy to control, same has a simple preparation process and a stable quality, and is easy to industrially produce on a large-scale.

Eutectic form A of Elagolix and pyrimethamine, preparation method therefor and use thereof

Provided is crystal form A of N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16, 18-tetrazohexahexane-1,26-di-yl)bis(4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline-4-yl) benzene sulfonamide. The crystal form has good light stability, high-temperature stability, and high-humidity stability.

Crystal form a of NHE3 inhibitor, preparation method therefor and application thereof

A crystal form X of 3α-hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one, a preparation method of said crystal form and an application thereof in preparing a drug for treatment of central nervous system disease.

γ-aminobutyric acid modulator crystal form X, preparation method and application thereof

Forms B and C of (R)&#x2014;N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide are stable under the conditions of light, high temperature and high humidity.

Forms of (R)-N-(4-chlorophenyl)-2-(cis-4-(6-fluoroquinolin-4- yl)cyclohexyl)propanamide

Growing community of inventors

Shenzhen, China

Dongxu Yi